Cargando…

Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment

Oncolytic viruses (OVs) are novel anti-tumor agents with the ability to selectively infect and kill tumor cells while sparing normal tissue. Beyond tumor cytolysis, OVs are capable of priming an anti-tumor immune response via lysis and cross-presentation of locally expressed endogenous tumor antigen...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Lucia, Maria, Cotugno, Gabriella, Bignone, Veronica, Garzia, Irene, Nocchi, Linda, Langone, Francesca, Petrovic, Biljana, Sasso, Emanuele, Pepe, Simona, Froechlich, Guendalina, Gentile, Chiara, Zambrano, Nicola, Campadelli-Fiume, Gabriella, Nicosia, Alfredo, Scarselli, Elisa, D’Alise, Anna Morena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658578/ https://www.ncbi.nlm.nih.gov/pubmed/33209980 http://dx.doi.org/10.1016/j.omto.2020.10.006

Ejemplares similares

Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis
por: Sasso, Emanuele, et al.
Publicado: (2020)

Generation of a Retargeted Oncolytic Herpes Virus Encoding Adenosine Deaminase for Tumor Adenosine Clearance
por: Gentile, Chiara, et al.
Publicado: (2021)

Integrity of the Antiviral STING-mediated DNA Sensing in Tumor Cells Is Required to Sustain the Immunotherapeutic Efficacy of Herpes Simplex Oncolytic Virus
por: Froechlich, Guendalina, et al.
Publicado: (2020)

A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells
por: Leoni, Valerio, et al.
Publicado: (2017)

Generation of a Novel Mesothelin-Targeted Oncolytic Herpes Virus and Implemented Strategies for Manufacturing
por: Froechlich, Guendalina, et al.
Publicado: (2021)

Retargeting Strategies for Oncolytic Herpes Simplex Viruses
por: Campadelli-Fiume, Gabriella, et al.
Publicado: (2016)

Simultaneous Insertion of Two Ligands in gD for Cultivation of Oncolytic Herpes Simplex Viruses in Noncancer Cells and Retargeting to Cancer Receptors
por: Leoni, Valerio, et al.
Publicado: (2018)

Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins
por: Petrovic, Biljana, et al.
Publicado: (2017)

Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells
por: Passariello, Margherita, et al.
Publicado: (2020)

HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses
por: Menotti, Laura, et al.
Publicado: (2018)

Adenovirus Encoded Adjuvant (AdEnA) anti-CTLA-4, a novel strategy to improve Adenovirus based vaccines against infectious diseases and cancer
por: D’Alise, Anna Morena, et al.
Publicado: (2023)

Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells
por: Petrovic, Biljana, et al.
Publicado: (2018)

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion
por: D'Alise, Anna Morena, et al.
Publicado: (2021)

VENUS, a Novel Selection Approach to Improve the Accuracy of Neoantigens’ Prediction
por: Leoni, Guido, et al.
Publicado: (2021)

Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling
por: Passariello, Margherita, et al.
Publicado: (2019)

Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies
por: Sasso, Emanuele, et al.
Publicado: (2018)

Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers
por: Vannini, Andrea, et al.
Publicado: (2023)

The Engineering of a Novel Ligand in gH Confers to HSV an Expanded Tropism Independent of gD Activation by Its Receptors
por: Gatta, Valentina, et al.
Publicado: (2015)

Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activity
por: Seclì, Laura, et al.
Publicado: (2023)

Efficacy of Systemically Administered Retargeted Oncolytic Herpes Simplex Viruses—Clearance and Biodistribution in Naïve and HSV-Preimmune Mice
por: Vannini, Andrea, et al.
Publicado: (2023)

Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade
por: D’Alise, Anna Morena, et al.
Publicado: (2019)

Towards a Precision Medicine Approach and In Situ Vaccination against Prostate Cancer by PSMA-Retargeted oHSV
por: Vannini, Andrea, et al.
Publicado: (2021)

Immunotherapeutic Efficacy of Retargeted oHSVs Designed for Propagation in an Ad Hoc Cell Line
por: Vannini, Andrea, et al.
Publicado: (2021)

Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy
por: D’Alise, Anna Morena, et al.
Publicado: (2023)

Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma
por: Appolloni, Irene, et al.
Publicado: (2021)

Genotype of Immunologically Hot or Cold Tumors Determines the Antitumor Immune Response and Efficacy by Fully Virulent Retargeted oHSV
por: Gianni, Tatiana, et al.
Publicado: (2021)

A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors
por: Leoni, Valerio, et al.
Publicado: (2018)

A long non-coding SINEUP RNA boosts semi-stable production of fully human monoclonal antibodies in HEK293E cells
por: Sasso, Emanuele, et al.
Publicado: (2018)

Spotlight on… Gabriella Campadelli-Fiume
por: Campadelli-Fiume, Gabriella
Publicado: (2018)

Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases
por: Leoni, Valerio, et al.
Publicado: (2015)

Preclinical Therapy of Disseminated HER-2(+) Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus
por: Nanni, Patrizia, et al.
Publicado: (2013)

High-Throughput Monoclonal Antibody Discovery from Phage Libraries: Challenging the Current Preclinical Pipeline to Keep the Pace with the Increasing mAb Demand
por: Zambrano, Nicola, et al.
Publicado: (2022)

One-Step Recovery of scFv Clones from High-Throughput Sequencing-Based Screening of Phage Display Libraries Challenged to Cells Expressing Native Claudin-1
por: Sasso, Emanuele, et al.
Publicado: (2015)

The Epithelial αvβ3-Integrin Boosts the MYD88-Dependent TLR2 Signaling in Response to Viral and Bacterial Components
por: Gianni, Tatiana, et al.
Publicado: (2014)

Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries
por: Cembrola, Biancamaria, et al.
Publicado: (2019)

Novel Combinations of Human Immunomodulatory mAbs Lacking Cardiotoxic Effects for Therapy of TNBC
por: Vetrei, Cinzia, et al.
Publicado: (2021)

The common H232 STING allele shows impaired activities in DNA sensing, susceptibility to viral infection, and in monocyte cell function, while the HAQ variant possesses wild-type properties
por: Froechlich, Guendalina, et al.
Publicado: (2023)

αvβ6- and αvβ8-Integrins Serve As Interchangeable Receptors for HSV gH/gL to Promote Endocytosis and Activation of Membrane Fusion
por: Gianni, Tatiana, et al.
Publicado: (2013)

New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC
por: Lembo, Rosa Rapuano, et al.
Publicado: (2022)

Dissecting the role of MPS1 in chromosome biorientation and the spindle checkpoint through the small molecule inhibitor reversine
por: Santaguida, Stefano, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_6vjfj9nptggpb9rkbhoms1u7l1